Objective: To investigate changes in serum-advanced glycosylation end product (AGE) levels in gestation diabetic mothers (GDMs) and its relationship with adverse fetal outcome.
Introduction
The incidence of gestational diabetes mellitus (GDM) is increasing each year, currently at 7% of all pregnancies in the United States. Further 3.9 to 7.4% of Asian/Pacific Islanders' risk factors for GDM mainly include older maternal age, a higher body mass index, and so on. 1 Women with GDM in mid-and late gestation with satisfactory blood glucose control still have a significantly higher incidence of congenital malformation and fetal distress compared with mothers without GDM. 2 The cause or mechanism by which women with normoglycemia still develop adverse fetal growth and development remains unclear. Research in recent years found that advanced glycosylation end product (AGE) levels were significantly higher in diabetics. 3 AGEs are involved in the pathogenesis and development of diabetic vasculopathy through various mechanisms. 4 Research in China and abroad focused mainly on diabetes and its effect on aging. 5, 6 To date, no clinical data are available on the relationship between gestational age, AGE levels, and fetal outcomes. This study addresses this potential relationship by investigating gestational AGEs and adverse fetal outcomes.
Methods

Participants
Clinical data of 72 cases of late GDMs and 60 cases of mid-GDMs aged between 18and 35 years, from May 2004 to January 2006, were collected as the GDM group. In addition, 45 of the 72 cases were recruited at mid-pregnancy (13 to 17 weeks of gestation). Seventy-two cases of normal mid-pregnancy and 80 cases of late-pregnancy mothers were observed as control groups. Inclusion criteria included regular antenatal examination of the mother and availability of complete data on delivery and neonatal histories. Diagnostic criteria of GDM were strictly defined as (1) fasting blood glucose of > 5.8 mmol/l on two or more occasions or (2) 2 h-75 g oral glucose tolerance test (OGTT): Fasting blood glucose >5.6 mmol/l, 1 h >10.3 mmol/l, 2 h >8.6 mmol/l with at least two out of the above three criteria in diagnosing GDM. Exclusion criteria: gestational impaired glucose tolerance (GIGT) and pregnant with normal OGTT; older than 35 years; multifetation; maternal illness, such as liver disease, renal disease, hypertension, heart disease, hyperlipemia, trace element deficiency and placenta praevia, which influences AGE levels, on medications that could interfere with the metabolism of glucose and fat, such as idomethacin, furosemide, thiazide diuretic, sodium phenytoin and cortisone.
To collect clinical outcomes, all pregnant women had regular antenatal examinations. The first antenatal examination was carried out at 20 weeks of gestation. This included a routine examination, reviewing the medical history, family history of diabetes, obesity, fetal death, stillbirth, large-for-date infant and repeated positive urine glucose. 2 h-75 g OGTT was performed and GDM was diagnosed if the results met the diagnostic criteria of GDM. Pregnant women without high-risk factors had GDM screening test at the gestation age of 24 weeks. Fasting, 1-and 2-h blood glucose levels after glucose intake were measured. If one of the above was abnormal, venous blood of 2 h-75 g OGTT was measured 3 days later. Those who were diagnosed at mid-gestation and at late-gestation age were designated as the mid-GDM group and late-GDM group, respectively. Pregnant women with GDM were hospitalized after being diagnosed. Medical nutrition control was first carried out and insulin was added if the effect of diet treatment was not sufficient. Glucose from peripheral blood was measured 10 times a day (morning fasting blood sugar, before, 1 hand 2 h after breakfast, lunch and supper). This was reduced to four times a day when the blood glucose trend was controlled. Fetal examination such as that of the fetal heart, fetal movement, fundal height, abdominal circumference, growth and development of fetus by type-B ultrasound, as well as that of any congenital abnormality also was started simultaneously. Mothers could be discharged when their blood glucose was normal and their 1-h post-prandial peripheral blood glucose was <7.8 mmol/l, 2-h peripheral blood glucose was <6.7 mmol/l, no sensation of hunger, they experienced no ketosis and the growth of fetus continued. Blood glucose was monitored 4 times a week after discharge.
Pregnant women in the control group also had regular antenatal examination for the same duration with a GDM screening test from the gestation age of 24 weeks. Their fasting blood glucose and 1-h and 2-h blood glucose after glucose intake were all normal. Those who had investigations at mid-gestation were designated as the mid-pregnancy normal control group and those investigated at late gestation were designated as latepregnancy normal control group. Fasting blood was used to measure AGEs and blood glucose.
All pregnant women received routine antenatal examination and blood glucose monitoring, and frequency antenatal examination was increased according to the pregnant woman's condition the fundal height and abdominal circumference were recorded, and fetal monitoring was intensified to exclude abnormality, polyhydramnios, hypoxiaand so on. Pregnancy was routinely terminated in the event of a severe fetal abnormality. Infants of women with GDM were treated as high risk and admitted to the neonatal department. They were assessed for their birth weight (and appropriateness for gestational age), congenital malformations, birth trauma (defined as injury of any organ or tissue of the newborn during delivery; for example, scalp injury, clavicle fracture, and so on), birth asphyxia (defined as no breath or breath restrained at birth or in the few minutes after birth) and hypoglycemia. Fetuses with abnormal antenatal findings were monitored intensively and fetal ultrasound/fetal echocardiography was performed wherever indicated. Newborns with normal antenatal findings were grouped into the normal group. Newborns with one abnormal antenatal finding were grouped into the abnormal group. Stillbirth and therapeutically aborted fetuses were also included in the abnormal group. First blood glucose level was measured within 1 h after birth and also at 3, 6, 12, 24 and 48 h. The disk diffusion method was used initially. Abnormal values were confirmed using venous blood. Hypoglycemia is defined as blood glucose level <2.2 mmol/l. 7 Newborns with hypoglycemia were treated according to our hypoglcemia guidelines.
Venous blood 2 h-75 g OGTT: Pregnant women had normal diet for 3 days and nothing orally 12 h before OGTT. Venous blood was obtained for fasting blood glucose through the vena mediana. Then 75 g of glucose was mixed into 200 to 300 ml of warm water and was consumed by the pregnant women within 3 to 5 min, Food with calorie was forbidden for the duration and blood glucose was measured 1 h and 2 h after taking the glucose.
Peripheral blood 2 h-75 g OGTT: Peripheral blood was obtained from the finger tip for measuring blood glucose thrice; other methods were the same as above.
Peripheral blood glucose: Peripheral blood was measured by the glucoside dehydrogenase method.
Venous blood glucose: 2 ml of venous blood was obtained and measured by the glucose oxidase method within 2 h (Beckman CX-7DELTA biochemistry analyzer, Beckman manufacturer, Inc., Fullerton, CA, USA).
Serum AGEs:2 ml of venous blood was obtained and centrifugated at 400 r.p.m. for serum, it was then refrigerated at À20 1C. A volume of 50 ml serum was diluted 100 times with 0.02 mol/l PBS (pH 7.4) for measuring the fluorescence value by fluorospectrophotometry (RF-5000 spectrofluorometer, Shimadzu corporation, Tokyo, Japan). 8, 9 Measurement of sCr and HbA1c: sCr was detected by a 7600 biochemistry analyzer, Hitachi high-technologies corporation (Tokyo, Japan). HbA1c was measured by a glycosylated hemoglobin analyzer (Bio-RM laboratories, Inc., Hercules, CA, USA). Normal reference value was 4 to 6%.
Serum AGE levels and fetal outcome L Guosheng et al Statistics All analyses were performed using SPSS 10.0. Numerical data were analyzed with the paired test, independent data with the doublesided t-test. Univariate analysis of co-variance and multiple logistic regression were carried out. a-Level was set at 0.05.
Results
There were no significant differences in age, gestation weeks, mean weight, gravidity and parity between the GDM and normal groups(P>0.05; see Tables 1 and 2 ). Women with GDM, whether at mid-or late gestation, had significantly higher blood glucose levels than those in the normal group (P<0.05, Table 3 ). AGE levels were also significantly higher (P<0.001, Table 4 ) Women with GDM in the mid-gestational period had significantly higher blood glucose level (Table 5 , t-test P<0.05). AGE levels were relatively high in both mid-and late-gestation GDMs with no statistically significant difference between the two groups (P>0.05). AGE levels in GDMs with abnormal infants were significantly higher than in GDMs with normal infants (P<0.05, Table 6 ). In univariate comparisons, there were no significant differences in AGE levels of GDMs with normal infants, infants with hypoglycemia and with large-for-gestational-age (LGA) infants (Table 7) . AGE levels in GDMs with abnormal fetuses and stillborns also showed no differences (P>0.05). However, GDMs with birth asphyxiated infants had significantly higher AGE levels than did corresponding GDMs with LGA, hypoglycemic and normal infants. Maternal AGE levels were highest in those with stillborn or with malformed fetuses compared with those in all other groups (P<0.05).
We used multiple logistic regression analysis to determine the effect of maternal age (x 1 ), serum AGE levels (x 2 ), fasting blood glucose values (x 3 ), response to treatment (x 4 ), blood glucose control (x 5 )and HbA1 C (x 6 ) on the incidence of perinatal complications. After controlling for maternal age (x 1 ), fasting blood glucose values (x 3 ), response to treatment (x 4 ) and blood glucose control (x 5 ), HbA1 C (x 6 ) logistic regression analysis showed that maternal serum AGE levels in GDMs (x 2 ) were a risk factor in the incidence of developing complications in newborn infants; OR ¼ 6.285, P<0.001, 95% CI: 2.56 to 15.524. Logistic regression model: Abbreviations: AGE, glycosylation end product; GDM, gestation diabetic mother. Abbreviations: AGE, glycosylation end product; GDM, gestation diabetic mother. Abbreviations: AGE, glycosylation end product; GDM, gestation diabetic mother.
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Discussion
This study showed that fasting blood glucose levels in late and particularly in mid-gestation GDMs were higher thanin mothers of similar gestation without this complication. The increase in glucose levels in mid-gestation as compared with that in late gestation was probably because of the initiation of treatment after diagnosis of GDM. As a result, blood glucose levels in late gestation, although still higher than normal controls, were within normal limits. AGE levels did not fall despite the fall in blood glucose levels. Mid and late gestation AGE levels were statistically significantly higher than in normal pregnancy controls at similar gestational ages. After treatment, blood glucose levels in mid-GDMs fell to normal levels by late gestation but, despite this, AGE levels at these gestations were elevated. The formation of AGEs is through glycosylation. Chronic hyperglycemia could lead to a large amount of AGE formation and accumulation in body tissues. GDM and type II diabetes have very similar pathogenesis and pathophysiology. Research has shown that GDM and type II diabetes patients' serum AGE levels are significantly higher than those in age-matched controls. 10 Studies from Buongioruo et al. showed that serum AGE levels were significantly higher in GDMs. Vlassara et al. confirmed that even in the absence of free glucose, once protein had been modified by AGEs, this process can self-perpetuate and may damage tissue through this 'self-amplification' process 11 this persistently raised AGE level throughout pregnancy could result in poor fetalmaternal outcome. Buongioruo et al. considered the high levels of AGEs in GDMs to affect the fetal-maternal balance, leading to changes in fetal outcome 12 when investigating diabetic rats, Xia Ling et al. found that hepatocytes, splenocytes, renal acinar and intercapillary endothelial cells, testicular Leydig cells and red blood cells, all showed accumulation of AGEs, leading to the corresponding pathology. 13 They also felt that persistently raised blood glucose was important in the rapid accumulation of AGEs in diabetic rat cells. Relatively high levels of AGEs in mid-and late-gestation GDMs not only directly affect the pregnant mothers, leading to pregnancy complications such as pregnancy-induced hypertension, prematurityand premature rupture of fetal membranes but also enter the fetal circulationthrough the placenta, with high fetal AGEs resulting in various fetal diseases and abnormal perinatal outcome. There is an association between high levels of maternal AGE and some adverse gestational outcomes, such as pre-eclampsia and infectious and inflammatory responses potentially involved in preterm delivery. 14 Our study showed that maternal AGE levels in GDMs with abnormal fetal outcome were higher than in those with normal fetal outcome. Further analysis showed that maternal AGEs in GDMs with fetal distress, fetal malformation and stillbirth were higher, particularly in those with fetal malformation and stillbirth. Multiple logistic regression found that AGEs are an important risk factor for abnormal outcome in infants of GDMs. Research showed that biformyl is an intermediary product in the formation of AGEs. 15 Biformyl is increased in diabetes. Biformyl can induce apoptosis in human embryonic lung epithelial cells. This would affect fetal growth and development, resulting in respiratory distress syndrome of the newborn. The Konishi et al. study showed that AGEs modulate changes in the trophoblastic layer, which adversely affect implantation of the embryo and placentation, leading to abnormal fetal conditions. 16 The pathogenicity of AGEs is broad. It can affect cell signaling and transduction through interaction with receptors. Examples are VEGF, TGF-b, IGFand PDGF activity of adhesion molecules leading to abnormal hyperplasia, differentiation, growth and development. Change in the expression of VEGF can lead to fetal cardiac malformation and fetal death. 17, 18 Other experiments showed that AGEs significantly increase the rate of myocardial apoptosis. 19 This was directly related to time and concentration and would affect the reconstruction of myocardial tissue. AGEs interact with glycosylated proteins and lipids, thereby changing the structure and effect of these proteins and inducing abnormal expression of cytokines. These abnormal changes occur most readily in small vessels, leading to vasculopathy in diabetics. When this occurs in the placental blood vessels of GDMs, this would affect placental function and consequently fetal growth and development, resulting Abbreviations: AGE, glycosylation end product; GDM, gestation diabetic mother. Serum AGE levels and fetal outcome L Guosheng et al in fetal distress, birth asphyxia, prematurity or intrauterine growth restriction. In our study, the incidence of fetal malformation and fetal distress was higher; 6.9 and 18.1%, respectively. There were two cases of cardiac malformation (one case of ASD, one case of PDA). During the formation of AGEs, large amounts of reactive oxygen species (ROS), ambi-COOH compound, are generated in the glycosylation process. The latter can further generate AGEs and ROS. An increase in AGEs in GDMs must be accompanied by an increase in the oxidation stress reaction. Furthermore, in diabetes, the activity of enzymes in removing oxygen-free radicals is impaired, leading to further accumulation of ROS. Placental dysfunction in diabetes may lead to oxygen-free radicals and its metabolites passing from the maternal to fetal circulation, resulting in fetal diseases. In vitro animal studies by Pieper found higher incidence of embryonic malformation in embryos cultured with 8-iso-TGF. 20 Viana et al. 21 first reported oxidative injury in embryonic rats. They thought that an increase in diabetic placental DNA base damage could induce mutations. If these mutations affect the genes in fetal development, it might lead to fetal malformations. Kotch cultured rat embryos in oxygenenriched medium and found neural tube defects. 22 Oxygen-free radicals can damage the placenta, and excess oxygen-free radicals suppress PGI 2 formation and enhance transformation of TXA 2 to TXB 2 . The latter stimulates vascular smooth muscle contractions and platelet aggregation, causing abnormal uterine placental fetal circulation (UPFC). Therefore, an imbalance in oxidative/ anti-oxidative and TXA 2 /PGI 2 systems is an important pathophysiological mechanism in intrauterine growth restriction (IUGR). 23 Despite our findings, there are a variety of potential limitations in our study. First, owing to its non-randomized design, there may be multiple confounding factors associated with both GDM-AGE levels and the outcomes we examined, which may actually lead to the associations we have shown or even causally relate to the outcomes examined. Despite this, the associations that we showed held even when we used multivariable logistic regression, and think they deserve further examination in larger studies. In addition, we did not conduct formal sample size calculations, and our study was underpowered to examine several of the outcomes. Finally, we are limited to an Asian/Chinese population. Therefore, these results will need to be examined in other populations to show consistency and generalizability.
In conclusion, there are multiple factors that lead to abnormal fetal outcome in GDMs. Hyperglycemia is an 'initiator' in inducing elevated AGE levels, abnormal arachidonic acid, creatine metabolism and oxidative stress reactions, which, individually or collectively, could affect the growth and development of the fetuses in GDM pregnancies. High AGEs may only be one potential factor in abnormal fetal outcome in GDMs. Our results may represent the 'tip of the iceberg' in examining this relationship and provide a foundation for further investigations in this subject. We believe our results support the need for large, multi-center studies to examine the biological underpinnings of abnormal fetal and neonatal outcomes in the setting of GDM and DM pregnancies.
